These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24605190)

  • 1. Influence of insurance benefit criteria on the administration rate of osteoporosis drugs in postmenopausal females.
    Lee JH; Lee YH; Moon SH; Lee YS;
    Clin Orthop Surg; 2014 Mar; 6(1):56-61. PubMed ID: 24605190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of low bone mass in postmenopausal Kuwaiti women residents in the largest province of Kuwait.
    Al-Shoumer KA; Nair V
    Arch Osteoporos; 2012; 7():147-53. PubMed ID: 23225292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.
    Frediani B; Bertoldi I; Pierguidi S; Nicosia A; Picerno V; Filippou G; Cantarini L; Galeazzi M
    Clin Drug Investig; 2013 Mar; 33(3):193-8. PubMed ID: 23456672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalent vertebral fractures predict subsequent radiographic vertebral fractures in postmenopausal Korean women receiving antiresorptive agent.
    Kim SH; Choi HS; Rhee Y; Kim KJ; Lim SK
    Osteoporos Int; 2011 Mar; 22(3):781-7. PubMed ID: 20533028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
    Mondockova V; Adamkovicova M; Lukacova M; Grosskopf B; Babosova R; Galbavy D; Martiniakova M; Omelka R
    BMC Med Genet; 2018 Sep; 19(1):174. PubMed ID: 30241506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis.
    Kaji H; Hisa I; Inoue Y; Naito J; Sugimoto T; Kasuga M
    J Bone Miner Metab; 2009; 27(1):76-82. PubMed ID: 19018454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
    Kamata Y; Minota S
    Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
    Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
    Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
    Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
    Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
    Angthong C; Rodjanawijitkul S; Samart S; Angthong W
    Acta Orthop Traumatol Turc; 2013; 47(5):318-22. PubMed ID: 24164940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.